The Hartford Healthcare Fund Class R4 HGHSX

Medalist Rating as of | See Hartford Funds Investment Hub
  • NAV / 1-Day Return 46.25  /  −1.30 %
  • Total Assets 775.8M
  • Adj. Expense Ratio
    1.350%
  • Expense Ratio 1.350%
  • Distribution Fee Level Average
  • Share Class Type Retirement, Medium
  • Category Health
  • Investment Style Large Blend
  • Min. Initial Investment 0
  • Status Open
  • TTM Yield 0.00
  • Turnover 49%

USD | NAV as of Oct 02, 2026 | 1-Day Return as of Oct 02, 2026, 12:11 AM GMT+0

Morningstar’s Analysis HGHSX

Will HGHSX outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

Still a worthy healthcare vehicle for the long haul.

Senior Analyst William Samuel Rocco

William Samuel Rocco

Senior Analyst

Summary

Hartford Healthcare’s team remains strong after several personnel changes in recent years, and its well-established and attractive approach remains intact. The strategy retains its People and Process Pillar ratings of Above Average.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings HGHSX

  • Current Portfolio Date
  • Equity Holdings —
  • Bond Holdings —
  • Other Holdings —
  • % Assets in Top 10 Holdings 47.1
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

11.62 94M
Healthcare

Johnson & Johnson

6.71 54M
Healthcare

Merck & Co Inc

6.42 52M
Healthcare

AbbVie Inc

4.33 35M
Healthcare

UnitedHealth Group Inc

4.27 34M
Healthcare

Elevance Health Inc

3.00 24M
Healthcare

Intuitive Surgical Inc

2.94 24M
Healthcare

Vertex Pharmaceuticals Inc

2.89 23M
Healthcare

CVS Health Corp

2.64 21M
Healthcare

Edwards Lifesciences Corp

2.32 19M
Healthcare

Sponsor Center